Figure 3

Effect of MPA on TFV and TAF inhibition of HIV infection and intracellular TFV-DP of blood CD4+ T cells. (a and c) Activated blood CD4+ T cells were pre-treated with indicated doses of TFV or TAF for 24hr and inoculated with HIV for 2hr. Following washout of virus after 2hr of culture, cells were incubated with MPA (1 × 10⁻⁷ M) at 5 days following infection, after which levels of p24 released in the culture media was measured by p24 enzyme-linked immunosorbent assay. Data were normalized to % of HIV infection with respect to infected controls without TFV or TAF pre-treatment and in the absence of MPA. (a) Percent of HIV infection on TFV treatment from 6 individual blood donors. (c) Percent of HIV infection on TAF treatment from 5 individual blood donors. Dark circles represent culture media in the absence of MPA and open circles represent culture media in the presence of MPA. Each circle represents one individual donor. *p < 0.05. (b and d) TFV-DP levels were measured by LC-MS/MS in purified blood CD4+ T cells pre-treated with MPA (1 × 10⁻⁷ M) for 24 hr followed by incubation with (b) TFV (3277 µM) and (d) TAF (2 µM) for an additional 24hr. Data were normalized to % fold change from control values. The bar represents the mean and SEM from 4 individual blood donors. Each circle represents one individual donor. *p < 0.05.